

Freedom of Information Request

Ref: 21-100

4 March 2021

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

- We can confirm that we do hold the information you are requesting

1. Within your health trust, how many patients have been treated in the past 3 months (Nov - Jan) for head and neck cancer (squamous cell carcinoma) with the following agents?

- Carboplatin (monotherapy or in combination with 5-FU) - 2
- Cisplatin (monotherapy or in combination with 5-FU) - 4
- Cetuximab with/without chemotherapy - 4
- Cetuximab with radiotherapy - 0
- Pembrolizumab monotherapy - 1
- Pembrolizumab with chemotherapy - 0
- Nivolumab - 4
- Docetaxel (monotherapy or in combination with 5-FU) - 0
- Fluorouracil (5FU) - 0
- Radiotherapy only - 24
- Other - 12

2. Within your health trust, how many patients have been treated in the past 3 months (Nov - Jan) with the following agents for renal cell carcinoma :

- Sunitinib - 29
- Avelumab + Axitinib - 3
- Axinitib - 6
- Cabozantinib - 20
- Everolimus - 0
- Lenvantinib + Everolimus - 4
- Nivolumab - 19
- Nivolumab + Ipilimumab - 5
- Pazopanib - 4
- Pembrolizumab + Axitinib - 0

- **Sunitinib** - 29
- **Temsirolimus** - 0
- **Tivozanib** - 4
- **Other** - 0

3. Within your health trust, how many patients have been treated in the past 3 months (Nov - Jan) with the following agents for colorectal cancer [CRC]?

- **Aflibercept** - 0
- **Bevacizumab** - 0
- **Cetuximab monotherapy** - 0
- **Cetuximab in combination with FOLFOX or FOLFIRI** - 0
- **Panitumumab monotherapy** - 0
- **Panitumumab in combination with FOLFOX or FOLFIRI** - 11
- **Nivolumab** - 3
- **Ramucirumab** - 0
- **Regorafenib** - 0
- **Sorafenib** - 0

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Director of Corporate Governance
 University Hospitals Bristol and Weston NHS Foundation Trust
 Trust Headquarters
 Marlborough Street
 Bristol
 BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information

(such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

Freedom of Information Team
University Hospitals Bristol and Weston NHS Foundation Trust